Macquarie believes the peptide CDMO market is poised for strong medium-term growth, supported by accelerating demand. The brokerage expects the market to expand from nearly $4 billion in 2025 to around $20 billion-$25 billion by 2030.
Macquarie believes the peptide CDMO market is poised for strong medium-term growth, supported by accelerating demand. The brokerage expects the market to expand from nearly $4 billion in 2025 to around $20 billion-$25 billion by 2030.